- Home
- ANVS vs SKYA Comparison
ANVS vs SKYA Comparison
Compare ANVS & SKYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | SKYA |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 59.7M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ANVS | SKYA |
|---|---|---|
| Price | $1.15 | $2.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 812.0K | 409.7K |
| Earning Date | 11-11-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $204,120.00 |
| Revenue This Year | N/A | $35,369.33 |
| Revenue Next Year | N/A | $9.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $0.91 |
| 52 Week High | $5.50 | $2.07 |
Technical Indicators
Market Signals| Indicator | ANVS | SKYA |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 76.66 |
| Support Level | $1.14 | $0.97 |
| Resistance Level | $1.43 | N/A |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 8.47 | 92.06 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
About SKYA SkyAI Inc. Common Stock
SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company's platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.